<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Direct oral anticoagulants in patients with cancer

descriptionPublicationkeyboard_double_arrow_right Article 02 Jul 2019 United States English Publisher:Oxford University Press (OUP)Journal:American Journal of Health-System Pharmacy, volume 76, pages 1,019-1,027 (issn: 1079-2082, eissn: 1535-2900,

Authors: Bossaer, John B.; Covert, Kelly L.;

doi: 10.1093/ajhp/zxz095

pmid: 31361880

Direct oral anticoagulants in patients with cancer

- Summary
- Subjects
- Metrics

Abstract

AbstractPurposeThis review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation.SummaryThe introduction of DOACs into clinical practice changed the way thrombotic complications are managed and prevented in diverse patient populations, including VTE and atrial fibrillation. Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients due to superiority over vitamin K antagonists in preventing recurrent VTE. Therefore, widespread DOAC use for VTE in patients with active cancer has not been adopted.ConclusionRecent randomized clinical trials (SELECT-D, Hokusai VTE Cancer) have provided evidence that DOACs may have a role in treating VTE in cancer patients.

Country

United States

Related Organizations

East Tennessee State University
United States

Keywords

Vitamin K, Administration, Oral, Anticoagulants, Standard of Care, Venous Thromboembolism, Heparin, Low-Molecular-Weight, Pharmacy and Pharmaceutical Sciences, Pharmacy Practice, Treatment Outcome, Risk Factors, Neoplasms, 616, Atrial Fibrillation, cancer, Humans, oral anticoagulants, Randomized Controlled Trials as Topic

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average